Benitec Biopharma (NASDAQ:BNTC) vs. NexImmune (NASDAQ:NEXI) Financial Comparison

Benitec Biopharma (NASDAQ:BNTC) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Benitec Biopharma and NexImmune, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	0	0	7	2	3.22
NexImmune	0	0	0	0	0.00

Benitec Biopharma presently has a consensus target price of $24.43, indicating a potential upside of 116.18%. Given Benitec Biopharma’s stronger consensus rating and higher possible upside, research analysts plainly believe Benitec Biopharma is more favorable than NexImmune.

Volatility and Risk

Benitec Biopharma has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, NexImmune has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Valuation and Earnings

This table compares Benitec Biopharma and NexImmune”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80,000.00	3,312.31	-$21.75 million	N/A	N/A
NexImmune	N/A	N/A	-$32.34 million	($18.54)	-0.01

Benitec Biopharma has higher revenue and earnings than NexImmune.

Profitability

This table compares Benitec Biopharma and NexImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-44.61%	-41.25%
NexImmune	N/A	-534.32%	-213.72%

Insider & Institutional Ownership

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 9.9% of NexImmune shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by company insiders. Comparatively, 14.9% of NexImmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Benitec Biopharma beats NexImmune on 9 of the 11 factors compared between the two stocks.

About Benitec Biopharma

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.